120 related articles for article (PubMed ID: 38010108)
1. Safety, pharmacokinetics, and target engagement of a brain penetrant RIPK1 inhibitor, SAR443820 (DNL788), in healthy adult participants.
Hincelin-Mery A; Nicolas X; Cantalloube C; Pomponio R; Lewanczyk P; Benamor M; Ofengeim D; Krupka E; Hsiao-Nakamoto J; Eastenson A; Atassi N
Clin Transl Sci; 2024 Jan; 17(1):e13690. PubMed ID: 38010108
[TBL] [Abstract][Full Text] [Related]
2. DNL104, a Centrally Penetrant RIPK1 Inhibitor, Inhibits RIP1 Kinase Phosphorylation in a Randomized Phase I Ascending Dose Study in Healthy Volunteers.
Grievink HW; Heuberger JAAC; Huang F; Chaudhary R; Birkhoff WAJ; Tonn GR; Mosesova S; Erickson R; Moerland M; Haddick PCG; Scearce-Levie K; Ho C; Groeneveld GJ
Clin Pharmacol Ther; 2020 Feb; 107(2):406-414. PubMed ID: 31437302
[TBL] [Abstract][Full Text] [Related]
3. Randomized clinical study of safety, pharmacokinetics, and pharmacodynamics of RIPK1 inhibitor GSK2982772 in healthy volunteers.
Weisel K; Scott NE; Tompson DJ; Votta BJ; Madhavan S; Povey K; Wolstenholme A; Simeoni M; Rudo T; Richards-Peterson L; Sahota T; Wang JG; Lich J; Finger J; Verticelli A; Reilly M; Gough PJ; Harris PA; Bertin J; Wang ML
Pharmacol Res Perspect; 2017 Dec; 5(6):. PubMed ID: 29226626
[TBL] [Abstract][Full Text] [Related]
4. A phase I randomized, double-blinded, placebo-controlled study assessing the safety and pharmacokinetics of RIPK1 inhibitor GFH312 in healthy subjects.
Lickliter J; Wang S; Zhang W; Zhu H; Wang J; Zhao C; Shen H; Wang Y
Clin Transl Sci; 2023 Sep; 16(9):1691-1703. PubMed ID: 37345561
[TBL] [Abstract][Full Text] [Related]
5. A phase I randomized study to evaluate safety, pharmacokinetics, and pharmacodynamics of SIR2446M, a selective RIPK1 inhibitor, in healthy participants.
Sun ALA; Gillies JD; Shen Y; Deng H; Xue F; Ma Y; Song L
Clin Transl Sci; 2024 Jul; 17(7):e13857. PubMed ID: 38949195
[TBL] [Abstract][Full Text] [Related]
6. Safety, pharmacokinetics and target engagement of novel RIPK1 inhibitor SAR443060 (DNL747) for neurodegenerative disorders: Randomized, placebo-controlled, double-blind phase I/Ib studies in healthy subjects and patients.
Vissers MFJM; Heuberger JAAC; Groeneveld GJ; Oude Nijhuis J; De Deyn PP; Hadi S; Harris J; Tsai RM; Cruz-Herranz A; Huang F; Tong V; Erickson R; Zhu Y; Scearce-Levie K; Hsiao-Nakamoto J; Tang X; Chang M; Fox BM; Estrada AA; Pomponio RJ; Alonso-Alonso M; Zilberstein M; Atassi N; Troyer MD; Ho C
Clin Transl Sci; 2022 Aug; 15(8):2010-2023. PubMed ID: 35649245
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics, pharmacodynamics and safety of the novel C-X-C chemokine receptor 3 antagonist ACT-777991: Results from the first-in-human study in healthy adults.
Boof ML; Géhin M; Voors-Pette C; Hsin CH; Sippel V; Strasser DS; Dingemanse J
Br J Clin Pharmacol; 2024 Feb; 90(2):588-599. PubMed ID: 37752659
[TBL] [Abstract][Full Text] [Related]
8. Safety and Pharmacokinetics of HRS-2261, a P2X3 Receptor Antagonist, in Healthy Subjects: A Randomized, Double-Blind, Placebo-Controlled Phase 1 Study.
Fan Y; Zhang X; Zhang Q; Zheng L; Zhou R; Sun C; Wang X; Song K; He Z; Wang H; Zhang Q; Hu W
Clin Pharmacokinet; 2024 Mar; 63(3):293-302. PubMed ID: 38198010
[TBL] [Abstract][Full Text] [Related]
9. Lucerastat, an iminosugar with potential as substrate reduction therapy for glycolipid storage disorders: safety, tolerability, and pharmacokinetics in healthy subjects.
Guérard N; Morand O; Dingemanse J
Orphanet J Rare Dis; 2017 Jan; 12(1):9. PubMed ID: 28088251
[TBL] [Abstract][Full Text] [Related]
10. A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose, Multiple Dose, and Food Effect Trial of the Safety, Tolerability and Pharmacokinetics of Highly Purified Cannabidiol in Healthy Subjects.
Taylor L; Gidal B; Blakey G; Tayo B; Morrison G
CNS Drugs; 2018 Nov; 32(11):1053-1067. PubMed ID: 30374683
[TBL] [Abstract][Full Text] [Related]
11. Safety, Tolerability and Pharmacokinetics of Single and Repeat Doses of Vixotrigine in Healthy Volunteers.
Naik H; Steiner DJ; Versavel M; Palmer J; Fong R
Clin Transl Sci; 2021 Jul; 14(4):1272-1279. PubMed ID: 33278330
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics, Safety Profile, and Tolerability of Tetramethylpyrazine Nitrone Tablets After Single and Multiple Ascending Doses in Healthy Chinese Volunteers.
Zhu G; Wang L; Zhong S; Han S; Peng H; Tong M; He X
Eur J Drug Metab Pharmacokinet; 2024 Mar; 49(2):207-217. PubMed ID: 38381348
[TBL] [Abstract][Full Text] [Related]
13. Safety, Tolerability, and Pharmacokinetics of the Novel Hepatitis B Virus Expression Inhibitor GST-HG131 in Healthy Chinese Subjects: a First-in-Human Single- and Multiple-Dose Escalation Trial.
Li X; Liu Y; Yao H; Wang M; Gao L; Lou J; Mao J; Wu W; Zhou Y; Tang Y; Yan W; Hu Y; Ding C; Chen S; Niu J; Ding Y
Antimicrob Agents Chemother; 2022 May; 66(5):e0009422. PubMed ID: 35404074
[TBL] [Abstract][Full Text] [Related]
14. Safety, Tolerability, Pharmacokinetics and Quantitative Electroencephalography Assessment of ACD856, a Novel Positive Allosteric Modulator of Trk-Receptors Following Multiple Doses in Healthy Subjects.
Önnestam K; Nilsson B; Rother M; Rein-Hedin E; Bylund J; Anderer P; Kemethofer M; Halldin MM; Sandin J; Segerdahl M
J Prev Alzheimers Dis; 2023; 10(4):778-789. PubMed ID: 37874100
[TBL] [Abstract][Full Text] [Related]
15. Safety, pharmacokinetics and pharmacodynamics of branebrutinib (BMS-986195), a covalent, irreversible inhibitor of Bruton's tyrosine kinase: Randomised phase I, placebo-controlled trial in healthy participants.
Catlett IM; Nowak M; Kundu S; Zheng N; Liu A; He B; Girgis IG; Grasela DM
Br J Clin Pharmacol; 2020 Sep; 86(9):1849-1859. PubMed ID: 32198939
[TBL] [Abstract][Full Text] [Related]
16. Safety, pharmacokinetics and pharmacodynamics of HRS-7535, a novel oral small molecule glucagon-like peptide-1 receptor agonist, in healthy participants: A phase 1, randomized, double-blind, placebo-controlled, single- and multiple-ascending dose, and food effect trial.
Wu J; Zhou R; Zhang Q; Zhang Q; Qin H; Ye Z; Xu Y; Feng S; Shu C; Shen Y; Fan Y; Wang Q; Du Y; Hu W
Diabetes Obes Metab; 2024 Mar; 26(3):901-910. PubMed ID: 38100147
[TBL] [Abstract][Full Text] [Related]
17. Safety, Tolerability and Pharmacokinetics of Icapamespib, a Selective Epichaperome Inhibitor, in Healthy Adults.
Silverman MH; Duggan S; Bardelli G; Sadler B; Key C; Medlock M; Reynolds L; Wallner B
J Prev Alzheimers Dis; 2022; 9(4):635-645. PubMed ID: 36281667
[TBL] [Abstract][Full Text] [Related]
18. Safety and Pharmacokinetics of the Oral TYK2 Inhibitor PF-06826647: A Phase I, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study.
Singh RSP; Pradhan V; Roberts ES; Scaramozza M; Kieras E; Gale JD; Peeva E; Vincent MS; Banerjee A; Fensome A; Dowty ME; Winkle P; Tehlirian C
Clin Transl Sci; 2021 Mar; 14(2):671-682. PubMed ID: 33290616
[TBL] [Abstract][Full Text] [Related]
19. Phase 1 Single Ascending and Multiple Ascending Dose Studies of Phosphodiesterase-9 Inhibitor E2027: Confirmation of Target Engagement and Selection of Phase 2 Dose in Dementia With Lewy Bodies Trial.
Landry IS; Aluri J; Schuck E; Ino M; Horie K; Boyd P; Reyderman L; Lai R
Alzheimer Dis Assoc Disord; 2022 Jul-Sep 01; 36(3):200-207. PubMed ID: 35700341
[TBL] [Abstract][Full Text] [Related]
20. Clinical Pharmacokinetics and Safety of ALZ-801, a Novel Prodrug of Tramiprosate in Development for the Treatment of Alzheimer's Disease.
Hey JA; Yu JY; Versavel M; Abushakra S; Kocis P; Power A; Kaplan PL; Amedio J; Tolar M
Clin Pharmacokinet; 2018 Mar; 57(3):315-333. PubMed ID: 29063518
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
